Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401818 | 0.84 | KDM4E (0.49) | — | |
| SCHEMBL2401104 | 0.81 | S1PR1 (0.40) | TRPV3 | |
| SCHEMBL2402288 | 0.80 | KCNH2 (0.42) | TRPV3KCNH2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL3558725 | 0.80 | ADORA3 (0.42) | — | |
| SCHEMBL2401639 | 0.76 | SYK (0.39) | — | |
| SCHEMBL3629880 | 0.75 | PTGES (0.39) | PTGES | |
| SCHEMBL2401890 | 0.74 | KDM4E (0.35) | KCNH2PTGES | |
| SCHEMBL2403548 | 0.72 | SYK (0.44) | — | |
| SCHEMBL2403597 | 0.72 | MTOR (0.37) | KCNH2PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL17348356 | 0.71 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641346-B | Pyridine and pyrimidine derivatives as mglur2 antagonists | HOFFMANN LA ROCHE | 2013-11-06 | — | — | CN | disclosed |
| US-8415380-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2011-10-27 | — | — | US | disclosed |
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | disclosed |
| CN-101641346-A | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | disclosed |
| EP-2142527-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | TRPV3 874/4885KCNH2 583/4885PIK3CD 2350/4885 |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | TRPV3 874/4885KCNH2 583/4885PIK3CD 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.